Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Review Of Reviews: Drug Review Profiles 2013

21 Jan 2014

Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.

Related Content

Randomization Required: Liver Signal Necessitated <em>Kadcyla</em> Trial With Control Arm

16 Apr 2013

Ado-Over: FDA Uses Prefix To Get Ahead Of Pull-Down Menu Problem

17 Apr 2013

Ariad Took Dismissive View Of CV Events In <em>Iclusig</em> Labeling Proposals

17 Dec 2013

FDA Looked To <em>Arava</em>’s Safety Experience In Gauging <em>Aubagio</em>’s Risks

19 Mar 2013

<em>Aubagio</em> Approval Reflects FDA’s Evolving View On Multiple Sclerosis Drugs

19 Mar 2013

<em>Eliquis</em> Approval Delayed By Fraud, Dispensing Errors In Pivotal Trial

18 Jun 2013

“Marginal” Mortality Benefit Belongs In <em>Eliquis</em>’ Label, But Not The Indication Statement, FDA Says

18 Jun 2013

<em>Breo</em> Inverts Traditional Path To COPD Indication For LABA Combinations

23 Jul 2013

The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival

20 Nov 2013

<em>Fulyzaq</em> Review Shows FDA Adapting Smoothly To Adaptive Trial Design

22 May 2013

A Question Of Identity: Drug & Botanical Perspectives On Manufacturing Clash In <em>Fulyzaq</em> Review

22 May 2013

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.